Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for treating various diseases worldwide. The company's product portfolio includes: - **EYLEA injection:** Treats wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy and macular edema following retinal vein occlusion. - **Dupixent injection:** Used for atopic dermatitis and asthma in adults and children. - **Libtayo injection:** Treats metastatic or locally advanced cutaneous squamous cell carcinoma. - **Praluent injection:** Targets heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults. - **REGEN-COV:** A treatment for COVID-19. - **Kevzara solution:** For treating rheumatoid arthritis in adults. - **Inmazeb injection:** Treats infections caused by Zaire ebolavirus. - **ARCALYST injection:** For cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome. - **ZALTRAP injection:** For intravenous infusion to treat metastatic colorectal cancer. The company is also developing product candidates for treating eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; as well as cancer, pain, and hematologic conditions. Regeneron has **collaboration and license agreements** with several notable companies, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Roche Pharmaceuticals and Kiniksa Pharmaceuticals. It also collaborates with the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Biomedical Advanced Research Development Authority and AstraZeneca PLC. Founded in 1988, Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, New York.